AstraZeneca (LON:AZN) Stock Price Crosses Above 200-Day Moving Average – Here’s What Happened

AstraZeneca PLC (LON:AZN) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of £133.11 and traded as high as £147.90. AstraZeneca shares last traded at £146.50, with a volume of 27,232,461 shares changing hands.

Wall Street Analyst Weigh In

AZN has been the topic of several research reports. Berenberg Bank lifted their target price on AstraZeneca from £145 to £160 and gave the stock a “buy” rating in a report on Tuesday, January 27th. Shore Capital Group reissued a “buy” rating on shares of AstraZeneca in a research note on Friday, January 16th. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a report on Thursday, January 15th. Citigroup started coverage on AstraZeneca in a research note on Tuesday, January 27th. They issued a “buy” rating and a £170 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on AstraZeneca from £105 to £110 and gave the stock a “sell” rating in a report on Thursday, January 15th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and an average price target of £145.83.

AstraZeneca Stock Performance

The business’s fifty day moving average price is £143.48 and its two-hundred day moving average price is £133.11. The company has a debt-to-equity ratio of 60.87, a quick ratio of 0.59 and a current ratio of 0.94. The stock has a market capitalization of £227.19 billion, a P/E ratio of 22.40, a P/E/G ratio of 0.86 and a beta of 0.23.

Insider Buying and Selling

In related news, insider Nazneen Rahman sold 297 shares of AstraZeneca stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of £134.96, for a total value of £40,083.12. Corporate insiders own 0.14% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.